Ligand Pharmaceuticals Inc. (LGND) is a publicly traded Healthcare sector company. As of May 21, 2026, LGND trades at $217.75 with a market cap of $4.17B and a P/E ratio of 27.80. LGND moved +4.88% today. Year to date, LGND is +13.39%; over the trailing twelve months it is +107.54%. Its 52-week range spans $93.58 to $247.38. Analyst consensus is strong buy with an average price target of $279.71. Rallies surfaces LGND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in LGND news today?
Ligand Sees 56% Royalty Surge, Reaffirms Guidance, Eyes XOMA Deal: Ligand reported Q1 revenues of $51.7 million, driven by a 56% year-over-year jump in royalty income to $43.0 million. The company reaffirmed its 2026 guidance, expecting the pending XOMA deal to add over 120 assets and roughly $25 million of royalties.
Ligand Sees 56% Royalty Surge, Reaffirms Guidance, Eyes XOMA Deal: Ligand reported Q1 revenues of $51.7 million, driven by a 56% year-over-year jump in royalty income to $43.0 million. The company reaffirmed its 2026 guidance, expecting the pending XOMA deal to add over 120 assets and roughly $25 million of royalties.
Does Rallies summarize LGND news?
Yes. Rallies summarizes LGND news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is LGND research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LGND. It does not provide personalized investment advice.
